Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that low-dose oral minoxidil for androgenetic alopecia was associated with a higher incidence of hypertrichosis and edema compared to previous studies, but it remains a generally well-tolerated treatment option.

This study found that low-dose oral minoxidil (≤5 mg/day) effectively increased hair number and diameter in men and women with androgenetic alopecia, and was generally well-tolerated with mostly mild adverse effects, although serious complications were rare and associated mainly with pre-existing heart conditions.

This study reported that combined oral finasteride and topical 5% minoxidil treatment in men with male-pattern hair loss improved hair growth by initiating anagen in pre-existing but deficient follicles, yet the growth rates remained unchanged and did not normalize hair productivity.

This case report describes a patient with advanced androgenetic alopecia who underwent a 6-month trial of topical minoxidil and oral finasteride, aiming to optimize hair regrowth without surgery.

This study found that there was a significant increase in Google searches for "oral minoxidil" following a New York Times article, suggesting heightened public interest in this treatment for androgenetic alopecia.

Lower doses of oral minoxidil can promote hair growth without major heart risks.

In this study, oral minoxidil (1.25 mg and 2.5 mg) and topical 5% minoxidil significantly promoted hair regrowth in men with androgenetic alopecia over six months, showing comparable efficacy across both oral and topical treatments.

This study concluded that oral and topical minoxidil have similar overall benefits in treating androgenetic alopecia, but topical minoxidil improved hair density more and had fewer adverse effects.

This systematic review found that both oral and topical minoxidil have similar efficacy in improving hair density and terminal hair density among patients with androgenetic alopecia, suggesting that oral minoxidil may be a viable second-line or adjunct treatment option.

After a New York Times article talked about using low-dose oral minoxidil for hair loss, more people started getting this drug prescribed, but this trend didn't last long.

This study found that combining Chuzhi Shengfa Tablets with either ketoconazole shampoo or 5% minoxidil foam significantly improved hair density, hair diameter, and reduced scalp oil in men with androgenetic alopecia, without increasing adverse reactions.

This study found that oral minoxidil improved hair density in women experiencing late alopecia due to chemotherapy and/or endocrine therapy, with 74% showing clinical improvement and statistically significant increases in hair shaft density reported in those assessed with trichoscopy.

In this randomized controlled trial, researchers found that a 2.5 mg daily dose of oral minoxidil was more effective than a 1 mg dose in improving hair growth parameters in patients with androgenetic alopecia over three months, with both doses being well tolerated.

This study found that oral minoxidil is associated with a higher proportional reporting of several cardiovascular adverse events compared to topical minoxidil in spontaneous FDA reports, but these signals should be interpreted as hypothesis-generating rather than evidence of clinical safety.

In this randomized controlled trial, oral minoxidil at 2.5 mg daily was more effective than topical minoxidil for increasing hair thickness, counts, and density in men with androgenetic alopecia, demonstrating more significant improvements and better compliance over six months.

This systematic review and meta-analysis found that oral minoxidil improved hair loss symptoms in many patients, with significant improvement in 35%, but 27% experienced adverse events, highlighting the need for further research to confirm its safety and efficacy.

This review suggests that low-dose oral minoxidil may be a safe option for treating hair disorders in children, while moderate and high doses may not be safe.

This review found that oral minoxidil, particularly in low doses, is effective and safe for treating various types of hair loss, including androgenic alopecia, and may offer advantages over other treatments, such as improved convenience and enhancement of male sexual function.

This integrative literature review found that oral Minoxidil is a favorable alternative for individuals intolerant to topical application, effectively treating various forms of alopecia, though side effects like increased hair growth and minor dermatological reactions are noted.

This study found that 14 days of low-dose aspirin reduced the predicted response to topical minoxidil in androgenetic alopecia patients from 50% to 27%, suggesting aspirin may inhibit minoxidil efficacy.

This review discusses the use of low-dose oral minoxidil for patterned hair loss and reports it may offer improved compliance and safety compared to topical minoxidil, but provides no new clinical findings.

This review of available data noted that oral minoxidil shows promise for treating various alopecia disorders, including androgenetic alopecia and alopecia areata, but high-quality studies are needed to better understand its effectiveness and mechanisms in these conditions.

This study reviewed literature on low-dose oral minoxidil as a treatment for hair loss, finding good compliance and tolerability, with mild adverse effects like hypertrichosis, which increase with higher doses.

This study found that combining oral minoxidil, oral dutasteride, and dutasteride mesotherapy was the most effective treatment for androgenetic alopecia, with improved outcomes at 12 months and a favorable safety profile, compared to other treatment combinations.

This letter discusses adverse events related to low-dose oral minoxidil for alopecia, highlighting age-related risks and stressing the importance of contraindication awareness with no new clinical results presented.

This review discusses the potential of low-dose oral minoxidil as a safe and effective treatment for certain hair disorders, including alopecia, but reports no new clinical results.

Low-dose oral minoxidil is effective and satisfying for treating hair loss in young people.

In this study, a daily low-dose regimen of oral minoxidil and finasteride over 12 months led to significant hair density improvements in over 92% of adult men with androgenetic alopecia, including those with advanced stages, though inter-rater reliability in photo assessments was modest.

This study found that for people with androgenetic alopecia, increasing the dosage of low-dose oral minoxidil is associated with improvements in hair diameter and density, but also raises the risk of hypertrichosis and cardiovascular adverse events.